Stanley Steemer Research Project Announced by airmid healthgroup Coincides with President Obama's Meeting with Irish Prime Minister

Research into indoor health announced during networking event with Irish PM

President Obama had his traditional annual meeting with Irish Prime Minister, Enda Kenny, during a St. Patrick's Day visit in Washington DC. A large number of Irish-American trade related events took place around the visit to highlight the recovery of the Irish economy, with particular focus on the growth of the med-tech and biomedical research sectors with American companies in Ireland.

airmid healthgroup was pleased to be among those attending the events. At a business networking lunch Dr John McKeon, Co-Founder of airmid healthgroup was delighted to introduce Joseph Gargiulo representing Stanley Steemer, to the Prime Minister and announce further research in the area of indoor aerobiology and indoor health. A recent airmid study involving Stanley Steemer was presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI). The study found the Stanley Steemer deep cleaning process was proven to remove up to 97 percent of surface allergens. The study evaluated air and surface samples taken before and after hot water extraction in 20 US homes. Additional findings revealed successful removal of 67% of airborne cat allergens as well. “This scientifically confirms what we’ve heard anecdotally from our customers with allergies and asthma for years,” said Justin Bates, president of Stanley Steemer, “and we are excited about moving into phase two of our research.”

This latest round of research is to look at broadening the data as well as developing novel technologies aimed at cleaning for a healthy home. The ultimate objective in phase two is to gain certification by the Asthma and Allergy Foundation of America.

“The data from the study is very impressive and validates the need for people to understand what a thorough cleaning can accomplish for asthma and allergy sufferers,” said Dr John McKeon, Co-Founder of airmid healthgroup, an independent biomedical research organization working with a number of US companies. “We are delighted to make this announcement today as Stanley Steemer is at the forefront of research in this crucial health focused consumer issue."

Continue Reading

Print

airmid healthgroup Reveals Up To 97% Allergen Reduction in Carpets and Furnishings

European research company study shows effectiveness of cleaning process in reducing allergen levels.

DUBLIN, February 25, 2013 – airmid healthgroup, a biomedical research organization specializing in aerobiology, today announced the results of a recent breakthrough study in domestic allergen reduction in carpets and soft furnishings. The study demonstrated that a proprietary hot water extraction process used with a commercial truck-mounted cleaner delivered up to 97 percent allergen reduction. The results will be presented at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting this week in San Antonio, Texas.

According to the Asthma and Allergy Foundation of America, approximately 50 million Americans – one in five – suffer from allergies. Approximately 40 million have indoor/outdoor allergies as their primary allergy. airmid’s environmental specialists have devoted significant resources to studying indoor allergens, and this most recent study of carpets and the indoor environment is the third to be released by airmid within the past year, including research presented at the 2012 Annual Meeting of the American College of Allergy, Asthma & Immunology last November.

“Our goal at airmid is to identify and evaluate situations where indoor air quality is a concern, and then work with corporate household names to provide the best possible solution,” said Dr. Bruce Mitchell, CEO airmid healthgroup. “Since bio-contaminants in indoor air represent a growing worldwide problem, we have placed particular emphasis on finding solutions to lower the levels of indoor allergens and microbiological exposures.”

Recently, airmid healthgroup undertook a study in Dublin, Ohio for Stanley Steemer, one of the largest professional deep cleaning companies. Twenty US homes were assessed to measure the impact of the company’s proprietary hot water extraction technology on levels of surface allergen in both carpets and soft furnishings. The study also assessed whether a reduction in airborne bio-aerosol exposure was possible.

Results show that the proprietary hot water extraction cleaning process was highly effective in reducing allergen levels in carpets and soft furnishings. Surface levels of dust mite allergens on carpets, for example, were reduced by 91 percent, of cat allergen by 95 percent, and of dog allergen by 97 percent. The cleaning process also resulted in a marked reduction in airborne cat allergen exposure. The process also effectively reduced exposure to airborne mold. These findings were paralleled by a reduction in airborne particle counts during room disturbance on three different used carpets in an environmental test chamber. Average total airborne particles were 78, 37 and 65 percent less in the presence of carpet samples that had undergone the hot water extraction cleaning process than in the presence of un-cleaned carpet samples.

“What we’ve shown is that effective cleaning plays an important part in the maintenance of good air quality, regardless of whether a room has hard floors or carpeting,” said Dr. Mitchell. “This proprietary hot water-based extraction cleaning process is very effective at reducing the levels of harmful bio-contaminants. To maintain the healthiest environment for occupants, we recommend hot water extraction cleaning two to three times per year and vacuuming at regular intervals.”

Print

airmid to attend the 2012 Annual General Meeting of the European Down and Feather Association in Dublin

airmid will attend the 2012 Annual General Meeting of the European Down and Feather Association (EDFA) in Dublin.

The purpose of the EDFA is to promote the interests of the European producers of bed feathers and down and producers of ready-made articles filled or processed from feathers and down, as well as their quality. In addition, it pursues the targets of making a contribution towards promoting fair business dealings and transactions, of informing its members of European quality regulations, and of encouraging the compliance with such regulations.

Topics to be covered during the two day meeting included will include Nomite™ and using social media for marketing. Dr J. Hedderich, Business manager of EDFA will also present a literature review on dust mite allergies related to natural fill pillows and quoted several recent studies including that Dr Horst Müsken from Bad Lippspringe .

airmid looks forward to playing an active role in the organisation in the future by bringing its aerobiology and biomedical contract research expertise to the members.

Continue Reading

Print

Tarkett FiberFloor® gains certification for healthy indoor air

tarkett-logoFollowing a series of real time biomedical studies and aerobiological research by airmid's world leading environmental specialists, the flooring giant Tarkett has achieved a coveted health related certification. Tarkett FiberFloor is now Certified asthma & allergy friendly™ by the Asthma and Allergy Foundation of America (AAFA) for both loose-lay (no glue) and adhered (glue-down) applications.

Much of the research centred around allergen removal validation studies in indoor climate controlled environmental test chambers.

During the floor certification process, the products were subjected to both physical and chemical tests to ensure they do not have properties that are likely to irritate both asthma and allergy symptoms in susceptible people - including low capacity for allergen retention, and low VOCs off gassing.

It is estimated that Americans spends over 90% of their time indoors and according to the EPA, the level of exposure to chemicals indoors can be five times greater than outdoors. Poor Indoor Air Quality (IAQ) is considered a leading factor for asthma and allergies symptoms.

Over 60 million people in the United States, nearly one out of five Americans, are affected by asthma and allergies. The number has doubled in the past 30 years and continues to grow.

testing-call-to-action

 

Continue Reading

Print

airmid Expands Microbiological Testing Services

airmid healthgroup has announced today that it is expanding its range of microbiological services in the area of antimicrobial surface activity and biocidal efficacy. This follows on from the recent success of airmid’s antimicrobial surface testing, which was showcased at the European Innovation Convention.

Antimicrobial surface technology has received growing media attention in recent years. Due to the increase in nosocomial infections and the requirement for infection control in commonly contaminated areas, such technologies are valued for their contribution to the control of infectious diseases. The ability to coat commonly used indoor surfaces such as textiles, plastics and ceramics is also broadening the applicability of the technology to sectors such as airline travel, cleanroom facilities and sports facilities. It must be stressed however that there are potential pitfalls that may be encountered when scaling up such technology from bench studies to the environment in which it is intended to be used. Possible difficulties include reduced efficacy due to coverage issues with the coating, deterioration of the surface activity over time, or the removal of the coating following conventional washing.

airmid healthgroup, a specialist in the area of indoor air biocontamination and antimicrobial testing, has a particular expertise in looking at these issues. airmid can carry out a number of internationally recognised test methods related to this area including ISO 27447, ISO 22196, and ISO 20743. Testing in line with standard protocols may well be required for national and international regulatory bodies or technical and legal compliance centres. However, airmid also has the ability to modify these tests to the requirements of our clients by varying experimental conditions such as the exposure time, concentrations, or types of organisms used. Furthermore, airmid can support laboratory-based research by scaling up a project into their world class environmental test chambers and through to beta testing actual products at locations where they are designed to be used.

John Fallon, PhD, who heads up the microbiology testing laboratory said airmid is uniquely placed to support the product development process because "we have the ability to carry out testing from the bench top in the lab, to testing in an environmental chamber and then on to environmental field trials."

The antimicrobial testing and consultative modifications are available now.

For more information call +3531 6336820

Print

airmid healthgroup Attends 11th World Filtration Congress in Austria

Air Filtration & Biomedical research representatives from airmid healthgroup will be attending the 11th World Filtration Congress in Austria during the week of the 16th-20th April. The Congress will be held in Graz, a Unesco World Heritage Site. Key aerobiology topics will undoubtedly be centred on airmid’s innovative techniques that identify, evaluate and address the potential hazardous nature of airborne pathogens, biological aerosols and ultrafine particles.

With core expertise in the area of preventing ill health due to indoor air pollutants, airmid healthgroup scientists apply their skills to evaluate the complex interactions of biological, chemical and physical properties associated with consumer products, and provide customers with a complete solution for healthy living and label claim validation.

“It is concerning that the emission of ultrafine particles, even from products with HEPA filtration, results in consumers being exposed to bacterial fragments and other noxious particulate materials”, said Dr Bruce Mitchell, Chairman at airmid healthgroup. “However, it is of no surprise given the composition of household dust can include bacteria, viruses, mold and toxins. Of course, exposure has the capacity to induce ill-health”!

Most microorganisms are of sub-micron particulate size. When dust in a room is disturbed, these particles can remain airborne for days at a time. Recirculation of the contaminated air serves to augment exposure and hence potential infectivity. Ultrafine particle exposure may be further increased by microorganism contamination of the unit with growth of viruses, bacteria and molds.

airmid healthgroup is a unique vertically integrated facility which combines molecular biology with state-of-the-art air sampling and particle counting in highly sophisticated environmental test chambers. Availing of such facilities, airmid healthgroup can follow nominated viruses, bacteria, molds and other toxic ultrafine particles as they become airborne and are distributed throughout the chamber. Our clients include the international standards body, Allergy Standards Ltd, who list Dyson, LG and Rabbit Air in their programs.

It is inevitable that media attention will continue to focus on negative health implications associated with ultrafine particles. airmid healthgroup, through applied research in microbiology, molecular biology, and aerobiology offers companies the opportunity to proactively address these issues.

 

Print

airmid healthgroup Helps Spring Air Develop World’s First asthma & allergy friendly Certified Mattress

More than 60 million American adults and children live with asthma or allergies, which are chronic respiratory diseases characterized by sneezing, wheezing, coughing and difficulty breathing. Bedrooms, beds – and mattresses in particular – can be major sources of asthma and allergy triggers, since they often harbour dust mites, pet dander, irritating chemicals and gases, and more. So it’s no surprise that patients frequently report night-time symptoms, difficulty sleeping, and morning congestion as some of their most common frustrations.

Now, the world’s first Certified asthma & allergy friendly™ mattress has been designed thanks to a successful research & development partnership between Spring Air and airmid healthgroup. airmid provided advanced research & design advice during the prototype and commercialization stages for Spring Air’s new-generation of Breathe™ mattresses.

THE RIGHT PARTNER
airmid’s unique research and scientific experience provided Spring Air with the capabilities and knowledge to manufacture a set of mattresses that could receive asthma & allergy friendly™ certification by the Asthma and Allergy Foundation of America (AAFA), the first certification of its kind for a mattress.

Spring Air, a leading US brand of mattresses, wished to continue their company tradition of innovative product positioning. Partnering with airmid healthgroup, an ISO 17025:2005 accredited testing laboratory for house dust mite allergen (Der p 1), they undertook a research and development project to construct a better product that would achieve certification.

THE BEST SCIENCE
The mattress development project focused on making the sleep environment more suitable for people with asthma and allergies. airmid used controlled environmental chambers and state of the art analytical technology and applied a three-stage testing process:

  • Stage 1 – Barrier Function of Encasing Materials
  • Stage 2 – Component Emission Testing
  • Stage 3 – Real-Time Allergen Testing on Constructed Product

"Since 1926, Spring Air has marketed innovative mattresses and sleep sets to the US consumer’” said Rick Robinson, President at Spring Air. “Today, our investment in ground-breaking research with our partner airmid healthgroup provides us a new and superior ability to develop even better products to make the bedroom healthier.”

“We’re excited to partner with a progressive company like Spring Air, and play a role in their efforts to innovate products with technological and marketing advantages,” said Dr. Bruce Mitchell, CEO at airmid healthgroup. “They join a growing list of successful companies that have leveraged our chamber and integrated analytical facilities and resources to provide their customers with the highest quality products.”

The certified matrasses are already available through the Costco web site.

Continue Reading

Print

Carpet and IAQ study from US Immunology Conference has Significant Media Pick Up

There was a huge amount of interest during the recent presentation by Dr Angela Southey of a research project carried out in the airmid healthgroup climate controlled test chambers. Dr Southey was one of the lead researchers on the project. The data was presented during the American Academy of Asthma Allergy and Immunology (AAAAI) Annual Meeting 2012, March 2-6, in Orlando Florida.

"We were delighted with the interest in the study from health care professionals and the media" said Dr Southey. The message picked up by the media was ‘Carpets may not be the culprit’ which is a break with the current thinking in some sectors of health care professionals. 

"We are very pleased this has been picked up by the media" said Dr Bruce Mitchell, airmid CEO, "our mission is to assist our clients’ research capabilities, generate high class data and most importantly convert it into value. The current study and the issue of biological and non-biological ultrafine particles is a great example of this".

Continue Reading

Print

airmid healthgroup announces increased sensitivity for Fel d 1 ELISA (SP301)

Indoor Biotechnologies, manufacturers of a comprehensive range of quantitative ELISA kits for allergens, have enhanced the sensitivity of the Fel d 1 ELISA. The improvement carried out by Indoor Biotechnologies is based on a modified biotinylation technique used to create the biotinylation detection antibody (BI-3E4).

airmid healthgroup will therefore report the new detection limit of 0.13ng/ml compared to a previous detection limit of 0.5ng/ml. Validation studies with the Internal Quality Control samples have been carried out according to the ISO 17025:2005 standard.

The new detection limits will be as follows:

Der p 1 1.00ng/ml or 0.025μg/g*

Fel d 1 0.13ng/ml or 0.003μg/g*

Der f 1 0.5ng/ml or 0.013μg/g*

Mite Group 2 0.25ng/ml or 0.006μg/g*

Phl p 5 0.4ng/ml or 0.01μg/g*

Amp Der p 1 20pg/ml

Amp Fel d 1 2.5pg/ml

*Limits are based on a standard volume PBST (2.5ml) and a standard weight of dust (0.1g).

airmid healthgroup works continually to enhance and develop our testing methods to ensure the most efficient service possible.

For further details contact: Máire Fox MSc, Laboratory Manger and Quality Manager.

Print

airmid healthgroup Demonstrates Baby Mattress As Effective Allergen Barrier

DUBLIN, Ireland, March 6th 2012

Bluebear Nursery today released the findings from an allergen barrier efficacy study, undertaken on one of their leading baby mattress brands, 'Aerosleep Baby Protect'. The study was conducted by Dublin-based airmid healthgroup, the world's first ISO accredited testing laboratory for house dust mite and cat allergen analysis. The results confirm AeroSleep's claim that the protective fabric provided a barrier that is at least 99.77% effective against House Dust Mite and Cat allergen.

aerosleepUnder the terms of the study, airmid provided laboratory testing services on the protective fabric on the 'AeroSleep Baby Protect ', a mattress protector manufactured by AeroSleep, and distributed by Bluebear Nursery in Ireland. Two allergen barrier tests were conducted that replicated Cat Allergen and House Dust Mite Allergen being pulled through the fabric by airflow and also mechanical agitation. airmid is already a recognized testing partner to the US asthma & allergy friendlyTM Certification Program.

bluebear nursery"Bluebear Nursery has been researching and distributing high-quality baby nursery products in Ireland since 2003", said Declan Power, Director at Bluebear Nursery. "Our investment in independent research with our partner, airmid healthgroup, provides our customers with the reassurance that science underpins our product claims relating to Allergen Barrier Efficacy".

"The results demonstrate that the protective fabric on Aerosleep Baby Protect Mattresses can be considered an effective allergen barrier," said Fraser Hodgson, chief operations officer at airmid. "They join other bedding manufacturers that have leveraged our testing resources to provide customers with independent science to support product health-related claims. Third-party testing is an important component of their customer value proposition and we're glad to play a role in their efforts".

Continue Reading

Print

airmid healthgroup Signs R&D Partnership With Bedding Manufacturer Spring Air

DUBLIN, IRELAND and WASHINGTON, DC--(March 16, 2011)

airmid healthgroup, a Dublin-based research facility for a wide range of consumer products including new sleep products, today announced a research and development partnership with Spring Air International, a leading US manufacturer of bedding products. Under the terms of the deal, airmid will provide advanced research & laboratory testing services for Spring Air's new-generation bedding products. airmid is already a recognized testing partner to the US asthma & allergy friendlyTM Certification Program. The agreement further extends the company's US market presence.

The deal was announced today during a business luncheon in Washington, D.C. to mark Ireland's strong commercial links with the US. Featuring Ireland's new Prime Minister, Enda Kenny, the event was organized by Enterprise Ireland, the government agency responsible for the development and growth of Irish enterprises in world markets.

"Since 1926, Spring Air has provided innovative mattresses and sleep sets to the US consumer," said Rick Robinson, President at Spring Air. "Our investment in ground-breaking research with our partner airmid healthgroup, will provide new and superior, third-party-validated, healthy sleep products."

"We're excited to partner with a progressive company like Spring Air," said Dr. Bruce Mitchell, chief executive officer at airmid. "They join other global bedding leaders that have leveraged our testing resources to provide customers with the highest quality products. These companies are proactive leaders in the global drive to reduce ill health due to indoor air pollutants - a major cause of the asthma and allergies that affect more than 70 million Americans. Third-party testing is an important component of their customer value proposition. We're glad to play a role in their efforts by helping them innovate products with technological and marketing advantages."

Continue Reading

Print